ABSTRACT BACKGROUND E-cigarette (EC) use is increasing exponentially worldwide. The early cardiovascular effects of
E lectronic cigarettes or E-cigarettes (EC) are gaining popularity worldwide as an alternative to smoking tobacco cigarettes (TC) with a 55% increase in users between 2013 and 2015 with growth in the United Kingdom occurring fastest in Europe (1) . The prevalence of EC use in the United Kingdom and United States is around 6% (2) , and 51% of users did so because they believed it to be less harmful than regular cigarettes (3) 95% CI: 1.20 to 2.66) (4) . Despite this, there remains little good quality evidence on the short-and longterm safety of these devices. Furthermore, conflicting advice from various public health bodies worldwide on the use of these devices has resulted in lack of clarity for policymakers as well as the public at large (5, 6) .
TC contain >7,000 chemicals, including exposing smokers to high levels of nicotine, carbon monoxide (CO), acrolein, and pro-oxidant compounds. Data from chemical analysis and toxicology studies suggest that exposure to toxic chemicals from EC is lower compared with exposure from TC (7, 8) . However, other studies have shown that there remains the presence of potentially harmful tobacco-specific alkaloids such as anabasine, myosmine, and b-nicotyrine in EC liquid cartridge samples tested (9) . The impact of nicotine on vascular health is also unclear.
Nicotine may accelerate the atherogenic process by binding to high-affinity nicotinic acetylcholine receptor cell surface receptors (10) . However, longerterm nicotine use appears not to accelerate atherogenesis but may contribute to acute cardiovascular events in the presence of cardiovascular (CV) disease (11) . The early vascular impact of switching from TC to EC-nicotine versus EC-nicotine-free is not known.
Endothelial dysfunction is the earliest detectable change in vascular health, and, importantly, it has consistently been shown to be associated with CV risk and long-term outcomes (12, 13) . We measured endothelial function using flow-mediated dilatation (FMD) and arterial stiffness by pulse wave velocity (PWV), 2 validated and independent predictors of CV risk above and beyond traditional risk factors (14, 15) . We conducted the current trial to address specific questions on the early CV effects of switching from TC to EC and the impact of nicotine itself on any early vascular changes that might be seen. George et al. As the parallel control arm expressed a preference to not be randomized, a propensity score was created with the binary outcome of randomized versus nonrandomized using logistic regression and subsequently used as an adjustment covariate in the regression models to allow for potential bias. Variables included in the propensity score included demographic data, blood pressure, CO levels, all measured biomarkers, FMD and vascular stiffness parameters, and smoking history (Online Table 1 ).
All analyses were conducted in SAS version 9.4
(SAS Institute Inc., Cary, North Carolina).
RESULTS
A total of 145 patients were recruited into the trial ( Figure 1) . A final number of 114 patients (40 TC, 37
EC-nicotine, 37 EC-nicotine-free) completed both visits. Baseline demographic data and smoking history among the 3 arms were comparable and are shown in Table 1 . There were no serious adverse events reported during the trial. Table 2 ). There was no statistically significant difference in FMD change between the EC-nicotine and EC-nicotine-free arms ( Table 2 , Central Illustration).
The interaction term between treatment and sex for the primary outcome of FMD change was statistically significant (p ¼ 0.009), therefore the subgroup analyses was performed by sex. The improvement in FMD was seen in both males and females for TC versus EC comparisons but significantly greater improvement in vascular function was seen in females who switched from TC to EC ( Table 3) .
As expected, exhaled CO levels were high at baseline and comparable among the 3 arms of the study (Table 1) . However, at the end of study, those with the SECONDARY OUTCOMES. There was no significant trend in difference among the 3 arms for other secondary outcomes including PWV, heart rate, and biomarkers of inflammation and platelet reactivity (Table 5 ). However, the interaction terms between treatment and smoking pack-years were significant for PWV (p ¼ 0.016) and heart rate (p ¼ 0.003).
Therefore, a subgroup analysis was done for these outcomes by smoking pack-years.
VASCULAR STIFFNESS AND BLOOD PRESSURE.
Smokers who smoked #20 pack-years also demon- HEART RATE. For smokers who smoked #20 packyears (n ¼ 31), resting heart rate significantly Values are regression coefficient (95% CI). *Adjusted for baseline of the outcome, baseline age (#40 years, >40 years), sex (male, female), and smoking pack-years (#20 pack-years, >20 pack-years).
of CV events was 13% lower with every 1% improvement in FMD (12) . As we have demonstrated with ageand sex-matched healthy volunteer FMD data from our lab, otherwise healthy but chronic TC smokers who switched to EC improved their vascular function, approaching values seen in healthy nonsmokers.
Within 1 month of switching from TC, we found a 1.5% improvement between TC and EC-nicotine-free arms, 1.4% improvement between TC and EC-nicotine arms, and a 1.5% improvement between TC and combined EC arms ( Table 2) . Adjusted mean percentage change in forearm flow-mediated dilation with 95% confidence intervals for subjects on electronic cigarettes (EC), EC-nicotine, and ECnicotine-free. In addition to these findings, we found a reduction in resting heart rate in the >20 pack-years cohort who switched to EC. The association between resting heart rate and CV events is well known (26, 27) and the link between smoking cessation and reduction in heart rate has been previously demonstrated in other studies (28) . However, this present study suggests that a switch from TC to EC might also achieve this early on in chronic smokers. A reduction in resting heart rate as seen in this cohort of high CV risk, chronic, heavy smokers would yield the greatest benefit, further supporting the benefits of these cohorts switching from TC to EC. Whether this might be a transient phenomenon or translates to more sustained benefits requires further investigation.
We stress that whereas this study provides new Values are regression coefficient (95% CI). Change in parameters adjusted for baseline of the outcome, baseline age (#40 years, >40 years), sex (male, female), and smoking pack-years (#20 pack-years, >20 pack-years). *Log-transformed.
CI ¼ confidence interval; CRP ¼ C-reactive protein; LDL ¼ low-density lipoprotein. Abbreviations as in Tables 1 and 2 .
when both products were accompanied by behavioral support.
STUDY LIMITATIONS. This was a single-center study. We could not perform a full 3-arm randomized controlled design as it was unethical for participants who wished to quit smoking to be allocated to the smoking arm. We created a propensity score as an adjustment covariate in the regression models to allow for any potential bias and the results remained consistent. Baseline characteristics of the cohorts were also comparable. The duration of effect tested was deliberately short as the primary purpose of the study was to investigate whether there were early vascular benefits from switching from TC to EC and the results are reassuring. However, longer follow-up is required to determine whether males also benefit to the same level as females do and whether these changes seen are sustained and to assess the impact of nicotine in EC.
There are many different EC devices available in the market, and we tested only 1 device for consistency of 
